650620login-checkCareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation |
April 5, 2023
CareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials
Companies at Forefront of Alternative Organ Supply Research to Address Organ Shortage
BRISBANE, Calif. & EDEN PRAIRIE, Minn.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.
Read the complete press release on CareDx.com.
650620login-checkCareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation |